If a free-floating brain could feel pain or ‘wake up,’ how would we know? That’s an important ethical question — and it’s one we need to ask more often as labs around the world create new organoids, or miniature human organs. To answer it we talked to Jay Gopalakrishnan at his ‘mini brain’ lab for centrosome and cytoskeleton biology in Düsseldorf, Germany.
As big pharma interest grows in bioelectronics medicine, Astellas swoops in for a startup developing wireless, grain-sized devices powered by ultrasound for CNS disease monitoring and intervention.
Analysis and insight on brain-computer interfaces (BCI). Stay updated as Singularity Hub discusses the most important trends and research related to BCIs.
For a while now, we’ve known there’s a complex interplay between our hormones, guts, and mental health, but untangling the most relevant connections within our bodies has proved challenging.
New research has found a single enzyme that links all three, and its presence may be responsible for depression in some women during their reproductive years.
Wuhan University medical researcher Di Li and colleagues compared the blood serum of 91 women aged between 18 and 45 years with depression and 98 without. Incredibly, those with depression had almost half the serum levels of estradiol – the primary form of estrogen our bodies use during our fertile years.
The technology I want to talk about today is something out of this world, but also a bit controversial There is a startup in Australia who are actually growing live human neurons and then integrating it into traditional computer chips… mind-blowing stuff!
Cerebral organoids at the air-liquid interface generate nerve tracts with functional output. https://www2.mrc-lmb.cam.ac.uk/cerebral-organoids-at-the-air…al-output/ “The capacity for this model to be used to investigate the way in which neurons connect up within the brain and with the spinal cord could have important implications for our understanding of a range of diseases. In particular defects in neuronal connectivity are thought to underlie various psychiatric illnesses, including schizophrenia, autism, and depression. ”
Cerebral organoids at the air–liquid interface generate diverse nerve tracts with functional output. https://www.readcube.com/articles/10.1038/s41593-019-0350-2 “Finally, through electrophysiological and co-culture studies, we demonstrate functionality of these tracts, which are even capable of eliciting coordinated muscle contractions in co-cultured mouse spinal cord–muscle explants. This approach is likely to be a useful new tool, not only because of its ease, but also due to its util-ity in studying axon guidance, tract formation, and connectivity in a human system”
What’s Wrong With Growing Blobs of Brain Tissue? https://www.theatlantic.com/science/archive/2018/04/what-hap…ns/558881/ “The stuff we really care about in the brain, like consciousness, are emergent phenomena—they arise from the collective workings of individual neurons, which create a whole that’s greater than the sum of its parts. The problem is that we don’t know at what level these phenomena emerge. A neuron is not conscious. A person is. What about all the steps in the middle? What about 2 million neurons? 20 million? 200 million?”
Elements is more than just a science show. It’s your science-loving best friend, tasked with keeping you updated and interested on all the compelling, innovative and groundbreaking science happening all around us. Join our passionate hosts as they help break down and present fascinating science, from quarks to quantum theory and beyond.
Researchers at Texas A&M University have developed the first molecular therapeutic for Angelman syndrome to advance into clinical development.
In a new article, published today in Science Translational Medicine, Dr. Scott Dindot, an associate professor and EDGES Fellow in the Texas A&M School of Veterinary Medicine and Biomedical Sciences’ (VMBS) Department of Veterinary Pathobiology, and his team share the process through which they developed this novel therapeutic candidate, also known as 4.4.PS.L, or GTX-102. Dindot is also the executive director of molecular genetics at Ultragenyx, which is leading the development of GTX-102.
Angelman syndrome (AS) is a devastating, rare neurogenetic disorder that affects approximately 1 in 15,000 live births per year; the disorder is triggered by a loss of function of the maternal UBE3A gene in the brain, causing developmental delay, absent speech, movement or balance disorder, and seizures.